1. Market Research
  2. > Pharmaceutical
  3. > Drug Development Market Trends
Market Spotlight: Waldenström Macroglobulinemia (WM)

Market Spotlight: Waldenström Macroglobulinemia (WM)

  • March 2018
  • 32 pages
  • ID: 5336338
  • Format: PDF
  • By Datamonitor Healthcare

Summary

Table of Contents

This Market Spotlight report covers the Waldenström Macroglobulinemia market, comprising key marketed and pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
 
Key Takeaways 
Datamonitor Healthcare estimates that in 2016, there were approximately 4,600 incident cases of Waldenström macroglobulinemia in people aged 40 years and over worldwide, and forecasts that number to increase to 6,000 incident cases by 2025. 

It is estimated that the majority of diagnosed cases worldwide were in males in 2016. 
Worldwide, the incidence of Waldenström macroglobulinemia is highest among individuals aged 60–79 years. Imbruvica, a small molecule tyrosine kinase inhibitor, is the only drug approved by the US Food and Drug Administration for Waldenström macroglobulinemia. 

The majority of industry-sponsored drugs in active clinical development for Waldenström macroglobulinemia are in Phase II, with only one drug in Phase III. 

Therapies in mid-to-late-stage development for Waldenström macroglobulinemia focus on targets such as the PI3K/AKT pathway, proteasome, Bruton’s tyrosine kinase, and cluster of differentiation 20. These drugs are administered via the oral, intravenous, and subcutaneous routes. 


There have been only two licensing and asset acquisition deals involving Waldenström macroglobulinemia drugs during 2013–18. The $50m collaboration agreement between Genmab and Novartis, pursuant to which Novartis intends to transition Arzerra (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications, was the largest deal. 

Velcade’s US parent product patent is set to expire in July 2022, which will open the door to generic entry. The distribution of clinical trials across Phase I–IV indicates that almost all trials for Waldenström macroglobulinemia have been in the early and mid-phases of development, with 96% of trials in Phase I–II, and only 4% in Phase III. 

The US has a substantial lead in the number of Waldenström macroglobulinemia clinical trials globally. France leads the major EU markets, while China has the top spot in Asia. 

Clinical trial activity in the Waldenström macroglobulinemia space is dominated by completed trials. Takeda, Celgene, and Novartis have the highest number of completed clinical trials for Waldenström macroglobulinemia, with 11, six, and five trials, respectively. 

Takeda leads industry sponsors with the highest number of clinical trials for Waldenström macroglobulinemia, followed by Celgene.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Liver Transplant Rejection - Pipeline Review, H2 2019

Liver Transplant Rejection - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Liver Transplant Rejection - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Liver Transplant Rejection - Pipeline Review, H2 2019, provides an overview ...

Global Organ Transplantation Market: World Market Review By Product Type, By Applications, By Region, By Country (2019 Edition): Forecast to 2024

Global Organ Transplantation Market: World Market Review By Product Type, By Applications, By Region, By Country (2019 Edition): Forecast to 2024

  • $ 2400
  • October 2019

Executive SummaryAccording to the report, the Global Organ Transplantation market is projected to display a robust growth represented by a CAGR of 6.50% during 2019 – 2024.Immunosuppressant drugs hold ...

Tracheostomy Products Market by Product, Technique, End-User, Region - Global Forecast to 2024

Tracheostomy Products Market by Product, Technique, End-User, Region - Global Forecast to 2024

  • $ 4950
  • September 2019

The tracheostomy products industry is projected to grow at a CAGR of 4.2% during the forecast periodThe tracheostomy products market size is projected to reach USD 220 million by 2024 from USD 179 million ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on